FIELD: medicine, pharmacy. SUBSTANCE: invention claims the budesonide aqueous solution with an anti- inflammatory effect that contains budesonide, propylene glycol, polyethylene oxide, benzoic acid, succinic acid, Trilon B, nipazole, thiourea and water. The solution can contain 2-hydroxypropyl-β-cyclodextrin additionally. Invention provides stability of the solution for 2 years and retention of its therapeutic effect. Invention can be used for treatment of patients with allergic, pollinosis and year-round rhinitis. EFFECT: improved properties, enhanced effectiveness of treatment. 4 cl, 2 tbl, 1 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE COMPOSITION WITH ANTI-INFLAMMATORY EFFECT | 2002 |
|
RU2203668C1 |
| CYCLOPHERONE-BASED PHARMACEUTICAL COMPOSITION OF LOCAL OR EXTERNAL APPLICATION FOR TREATMENT OF PURULENT-DESTRUCTIVE AFFECTION OF MUCOUS MEMBRANE AND SKIN, GENERAL-SYSTEM DISEASES IN CASE OF IMMUNODEFICIENCY CONDITIONS (VERSIONS) | 2008 |
|
RU2414221C2 |
| TOPICAL AND EXTERNAL TILORONE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PURULENT-DESTRUCTIVE MUCOSAL AND SKIN DISEASES, SYSTEMIC DISEASES IN IMMUNODEFICIENCY STATES | 2008 |
|
RU2401104C2 |
| LOCAL AND EXTERNAL PHARMACEUTICAL PRODUCT BASED OF LOW MOLECULAR INTERFERON INDUCER | 2007 |
|
RU2353354C1 |
| AGENT FOR TREATMENT OF DERMATOLOGICAL DISEASES | 2001 |
|
RU2197247C2 |
| PROPHYLAXIS COMPOSITION FOR BUCCAL CAVITY HEALTHCARE | 2004 |
|
RU2253435C1 |
| PHARMACEUTICAL COMBINED COMPOSITION FOR THE TREATMENT OF PURULENT WOUNDS ON THE BASIS OF FLUOROQUINOLONS (OPTIONS) | 2016 |
|
RU2682171C2 |
| PHARMACEUTICAL COMBINED COMPOSITION FOR LOCAL AND EXTERNAL USE ON BASIS OF DIOXIDINE | 2016 |
|
RU2667974C2 |
| AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIALLERGIC ACTION | 2012 |
|
RU2488402C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING EYE DISEASES RELATED TO EYE TISSUE METABOLIC DISEASE AND INFLAMMATORY EYE TISSUE INJURY | 2013 |
|
RU2521337C1 |
